а

acetic acid 4, 77 acoustic wave separation (AWS) 220, 221 adsorbent materials 3 - agarose/cellulose-based 4 - commercial 5, 6 -- suppliers 7 - with a high-density matrix 9 - ligand 4 adsorbents. see adsorbent materials adsorption 98 - capacity vs. concentration of vacant sites 100 - determination of 104 - expanded bed adsorption technology 1 - irreversible 101 - isotherms 6, 8, 16 - methods 328 - of protein monomer/aggregate on resin surface 101 - rate of adsorption of aggregate 102 adsorption-desorption rate 9 adsorptive filter materials 410 affinity chromatography (AC) 16 agarose 3, 16, 328, 488 alternating tangential flow (ATF) 386 anion exchange chromatography (AEX) 280, 379, 426, 441, 450, 482 anion exchanger 6, 16, 19, 99, 328 antibody technologies 358 aseptic transfer systems 413 automated fill system 418 automated KrosFlo perfusion system (aKPS) 215 automated single-use centrifugation solution 385 AWS. see acoustic wave separation (AWS) azeotrope 19

b

bacteria challenge testing 409, 410 bacterial resistance 298 bacteriophages 297 - adaptation 303 - concentration 302 – continuous purification of 325, 326 -- centrifugation 326 -- chromatography 328, 329 – – filtration 327 -- flocculation 326, 327 -- precipitation 326, 327 - cultivation 305 -- cellstat 310-314 -- cellstat productivity 314-322 -- chemostat 306-310 -- technical challenges 323-325 - ENKO 298 - INTESTI 298 - lambda 302 - latent period 300, 301 - life cycle 299-304 -- related parameters 301 - lysogenic 299 - multiplication 299 - properties determination 303-305 - selection 322, 323 – therapy 299 - tool in biotechnology and applications 297 - traits 298 baculovirus expression vector system (BEVS) 165 batch-based chromatography 257, 274 - separations 255 batch-based downstream processing 58 - high-level gap analysis 258 batch chromatography system 48 - chromatograms 236 - shared and segregated flow paths 49

Continuous Processing in Pharmaceutical Manufacturing, First Edition. Edited by Ganapathy Subramanian. © 2015 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2015 by Wiley-VCH Verlag GmbH & Co. KGaA.

batch fermentation 237 batch process 40, 258 - challenges to 258 - to continuous enabled by single-use technologies, transition from 259 benzalkonium chloride 411 binding capacity 4, 6, 11, 13, 21, 45, 99, 271, 324, 437, 488 BioCell MB(S) bioreactor 216 biological macromolecules 10 biologics 358 value chain 54 biomacromolecules 10 biopharmaceutical industry 116 - perfusion cell culture facilities 116 biopharmaceutical products 36, 115 - attributes/parameters 359 - minimal approach 359, 360 - quality-by-design approach 360, 361 – key steps for implementation 361 bioprocess containers (BPCs) 205, 424 bioreactors 125 benchtop, perfusion cultivation of CHO cells 121 – environment 115 - single-use 155 biosimilar product development 358. see also critical quality attributes (CQAs) - quality attributes and 361, 362 - quality guidance, factors 362 - quality, safety, and efficacy 362-364 BioSMB technology 40-44 – continuous multicolumn chromatography 260-263 – chronogram for bind and elute step with eight columns 262 – – loading zone 261 -- residual processing time (RPT) 263 -- switch time 263 - degree of freedom in design space 274 biotechnology, advancements made in 1 biotherapeutics molecule 71 bispecific monoclonal antibodies 59 - advantage of 59 - biopharma companies and portfolio 60 - first-generation 59 - future perspective 59 impact on big biopharma companies 63, 64 - improving downstream processing 61 -- MCSGP in value chain 61 -- MCSGP vs. batch chromatography 61 purification

-- advantages of MCSGP vs. batch chromatography 61 -- challenges in 60 bovine serum albumin (BSA) 6 BSA protein 10 - adsorption isotherms -- effect of salt concentration 8 -- and kinetics of 16-20 - breakthrough curves at various NaCl concentrations 18 - competitive adsorption 18 - constraints to net fluxes 23 - diffusion coefficients 19 - dynamic adsorption capacity 11 - effluent curves 10, 11, 13 - ion exchange equilibrium isotherms 16, 17 - recovery processes 10 -- EBA technology 11, 12 -- evaluation of the hydrodynamics 11, 12 -- Streamline Direct CST I 11, 12 - separation factor to myoglobin by 19 - streamline DEAE, operating conditions 11 с capsule filter 407, 408 capture applications, in downstream processing 232-234 CaptureSMB 233, 234 - chromatograms 236 - cycle 236 - twin-column 234, 235, 237, 251 CARR Centritech closed, continuous bioprocessing capable centrifuge, single-use module 219 case studies 46, 47, 167, 440 - acoustic separation 167 -- B. Braun Biostat B-DCU Quad systems 167 -- RANK Ligand (RANKL)-based vaccine production process 167 - alternating tangential flow (ATF) technology 176 – based cell retention -- aim in project 176

- ExpreS²ion established collaborations with 176
- bioreactor conditions 177
- -- perfusion rate 177
- to evaluate impact of continuous bioprocessing
- and potential of transforming such process into 46, 47
- fed-batch vs. perfusion culture for commercial mAb production 440–446

- integrated continuous processing cell retention devices 116, 125, 126 flowsheets 450, 451 - acoustic (ultrasonic) separators 134 - perfusion setup (BioSep) 167 - alternating tangential flow system 136-138 -- BioSep perfusion setup 168 - centrifugation 130, 131 -- cell count in the bioreactor 168, 169 - coupling to bioreactor in perfusion -- cells in perfusate over time at 1.5, 4.5, and 20 system 128 l working volume 175 - floating membrane devices 138 -- change in power setting for 4.5 l bioreactor - gravitational settlers 126-130 - hydrocyclones 131-134 runs 175 -- controlling the cell concentration through - in perfusion bioreactors bleed rate control 169, 170 – separation techniques employed for animal -- cultivations, parameters of interest 168 cell 127 -- development of perfusion rate profile 170 - rotating cylindrical filters 140, 141 -- effect of total dilution rate on culture - rotating disc filters 141 viability 170 - spin-filters 138-140 -- effects of BioSep settings on cell loss and - tangential flow-filtration 134-136 viability 169 cell-specific perfusion rate (CSPR) 342, -- initial testing of robustness of upstream 343 process in 1.5 l fermentations 170-173 CellTank 34, 341 -- process scale-up 174, 175 - perfusion runs using 346 -- scaling up and consistency in 4.5 l - prototype 341 fermentations 171, 173, 174 cellulose 3 results cell viability 344 -- cell counts achieved using perfusion centrifugal separation 385 centrifugation technology 177 -- effect of feed strategy 178 - centrifugal force and fluid-flow force, -- protein stability 179, 180 complete balance 389 -- VAR2CSA truncation variant 180 - continuous single-use centrifugation – yield improvements achieved using integrated with CMCC/SPTFF 259 fed-batch and concentrated perfusion 179 - separation by 385, 386 - semicontinuous affinity chromatography for - single-use 387 clinical and commercial manufacture charge-charge interaction 15 446-449 chemical-based drug 358 cation exchanger 4, 16 Chinese hamster ovary (CHO) cell lines 115, CellbagTM 340 340 cell banking 117 chitosan 77 cell culture process 75, 116, 155, 163, 367, 375, chlorhexadine 411 Chroma-Con (CaptureSMB process) 236 377, 389, 462, 463 - batch 462 chromatographic breakthrough (BT) - continuous 458, 463 curves 232 - fed-batch 482 chromatography techniques - four-column 50 - upstream 458 cell culture strategies 166 - global chromatography market 56, 57 - hydrophobic interaction chromatography cell density 75, 119, 160, 162, 339, 341, 342, 347-350, 353, 386, 443, 472, 474, 476 (HIC) 16, 41, 97, 99, 112, 237, 379 - decline 468 - IE-SMB 20-22 - downstream process challenges of high cell - ion exchange chromatography (IEC) 2 density cultures 386, 387 - membrane chromatography device 412 - high 135, 344, 347, 466, 482 - periodic countercurrent 143 - reverse phase 243 - steady-state 122 - viable 121, 342, 344, 350, 351 - semicontinuous 436, 437 Celligen bioreactors 216 - simulated moving bed (SMB) cell line development 366 chromatography 2, 195, 198, 235, 260

- used in downstream purification of biomolecules 55, 56 classic steady-state countercurrent chromatography 260 clean-in-place (CIP) operation 117, 234, 235 CMCC. see continuous multicolumn chromatography (CMCC) compounded annual growth rate (CAGR) 53 computational fluid dynamics (CFD) model 130, 139-141 - geometry selected using 142 - simulations 139, 141 contaminants 1, 21, 26, 280, 379, 386, 408, 410-412, 426 continuous animal cell perfusion processes. see perfusion processes continuous biomanufacturing 194 - biopharmaceutical manufacturing practices – potential impact of continuous processing on 490-492 - environmental objectives 213 - GMP facilities 210 multicolumn countercurrent chromatography in 251, 252 new manufacturing goals and considerations 209 - potential benefits 210, 211 - single-use 205-213 -- potential in next-gen products 212 - ThermoTM ScientificTM BioProcess Container assembly 208 continuous chromatography system 48 - shared and segregated flow paths 49 - vs. traditional batch processing methods 58 continuous disposable systems 340 continuous flow centrifugation 218-220 continuous multicolumn chromatography (CMCC) 259-262, 264, 271, 285, 287, 288, 291 - for Biological Production (BioSMB) 260 - 263continuous processing (CP) 183, 184 - in biomanufacturing (see continuous processing in biomanufacturing) - in biopharmaceutical manufacturing, difficulties 184 challenges in adoption of 190–193 - EMA guidelines 187 exploiting values of single-use technology 187 impact to reducing tank volumes and reduction in capital avoidance 294

- obstacles for implementation for biopharmaceuticals 485-487 - potential advantages in 187 -- ease in process development 188 -- improved product quality 187, 188 -- improved scalability 188 -- increased profitability 189, 190 -- sustainability 190 - potential impact on process economics 487 - 490- process analytical tools for multicolumn 252, 253 - quality by design 187 - rationale for 483-485 - single-use revolution to enable process intensification and 256-260 - values for pharmaceutical manufacturing 185, 186 - verification (CPV) 206 continuous processing in biomanufacturing - approved biopharmaceutical products produced by continuous cell culture 459 - brief history 458, 459 - challenges for implementing 462, 463 - opportunities for 459 -- better product quality 462 -- compact and flexible facilities 461 – higher process efficiencies 461 – higher process yields 459–461 -- stable and consistent production 462 - process characterization/validation -- complexity of a scale-down model for perfusion process 474, 475 process optimization/characterization for perfusion process 475 process validation 475 - process complexity 463 -- cell retention 463-466 -- high cell density 466, 467 -- longer run times 467-470 - process consistency/control 473, 474 - process scalability 470 -- process scale-up 471, 472 -- scale and capacity limitations 470, 471 continuous quality verification (CQV) 185, 206 controlled gene expression 358 controlled-shear affinity filtration (CSAF) concept 143 CP. see continuous processing (CP) CPP. see critical process parameter (CPP) CQAs. see critical quality attributes (CQAs) CQV. see continuous quality verification (CQV)

critical process parameter (CPP) 193, 195, 359, 378

- critical quality attributes (CQAs) 359
- based approach 357
- -- assessment of product quality and 366
- based clone 366
- -- selection/upstream process
- development 365, 366
- biologics, factors affecting 366
- expression host and recombinant cell line 366, 367
- -- process related 367
- cell line changes, and 370
- in formulation and stability 381
- -- formulation and quality attributes 381
- stability and quality attributes 382
- incomplete processing, of signal sequences and 373, 374
- protein production host and 368-369
- -- cell line changes 370
- host cell line and clone selection criteria 370–371
- in purification and formulation 379
- -- downstream processing 379-380
- major challenges, for monoclonal antibody manufacturing 379
- sequence variants identification by 371–373
 cross-flow filtration (CFF) 198
- cryopreservation 119, 187, 205, 340, 350-354
- culture media 116, 142, 166, 205, 207, 211, 415, 442, 443, 458
- cyclic steady state "fingerprint" 252 cytokines 166, 358

d

depth-flow filtration (DFF) 221 desorption kinetic constants – determination of 104 diethylaminoethyl (DEAE) 4 disk stack centrifuges 76 disposable – continuous processing 44–46 – filter capsules 408

- and single-use bioprocessing technologies 44
- downstream purification processes (DSP) 36, 84, 255, 291, 441
- basic steps, mAb production platform 72
- batch-based processing time with linear processing 257
- biomolecules, chromatography techniques 55, 56
- costs 54, 55

- evolution 259
- manufacturing schedules 37
- need for continuous manufacturing in 56–58
- timeline for batch production process 482
- transformation, to continuous processing 259
- unit operations and their availability in a disposable/single-use format 44
- with varying degree of multicolumn countercurrent process
- implementation 250
- Drosophila S2 system 165
- S2 expressed proteins 166
- DSP. see downstream purification processes (DSP)

е

- eight-column affinity adsorption 262
- chronogram 262
- electrostatic interaction 4
- endotoxins 71, 411, 412
- Escherichia coli 1, 115, 297
- ethylene-vinyl acetate (EVA) 404
- expanded bed adsorption/desorption of
- protein 10–13 expanded bed adsorption (EBA) technology 1, 2, 10
- expanded bed, modeling of 13-15
- expanded bed technology, protein capture by 3 extracapillary space (ECS) 217

f

- failure mode and effect analysis (FMEA) principles 50 fed-batch processes 115 – bioreactor and tanks in 117 fermentation 169–171, 438 – advancements in 257 – broth 78 – continuous 237, 251 – self-cycling 313 fermentor 412 filter membrane polymers 411 filter pore size 409 filter process validation 409
- filtration technologies 386, 406-413
- category 386
- fine purification 280, 281, 284
- cation exchange elution zone considerations 285, 287
- cation exchange loading zone optimization 284, 285

- 500 Index
 - effect of sample loading amount on 281, 283
 - effects of sample flow rate on 281
 - scaling-up membrane chromatography for continuous processing 283, 284

flexible production platforms 418

- construction and design types 418-422 - process location and flow 422, 423

flow rate 409

- formulation: continuous ultrafiltration 287 - 291
- Fourier transform infrared (FTIR) methodology 410

future processing and facility requirements

- downstream technologies 426, 427
- facilities and process design 428-431
- process platform design 430
- single-use engineering and design 427, 428
- upstream technologies 424-426

q

gap analysis 402 gas chromatography-mass spectrometry (GC-MS) methodology 410 gel filtration (GF) technique 97 generally recognized as safe (GRAS) 298 glycosylation variation 376 good manufacturing practice (GMP) 194, 207, 294, 405, 452

h

- height equivalent to a theoretical plate (HETP) 9 HIC. see hydrophobic interaction
- chromatography (HIC)
- high-performance liquid chromatography (HPLC) 9
- hollow fiber media exchange 214, 215
- hollow fiber perfusion bioreactors (HFPB) system 217
- cell culture 218
- fundamental characteristics 217
- posttranslational modifications 218
- reduction in both protein and DNA contamination 218
- "homemade" adsorbents 3, 4
- homogenous diffusion model 98
- host cell line, and clone selection criteria 370-371
- host cell proteins (HCPs) 71, 412
- hybrid systems 202, 203
- hydrocyclone 131, 133
- conventional showing primary and secondary vortices 132

- geometry suited for mammalian cell separation 132 - performance determined by 133 - properties perfusion devices 160 hydrogen bond interaction 4 hydrophobic interaction chromatography (HIC) 15, 16, 41, 97, 99, 112, 234, 237, 379 - rate-limiting step in 99 hydrophobic interactions 4, 16, 26, 97, 243

i

iCellis bioreactors 216 IE-SMB chromatography 16, 20, 21 - gradient IE-SMB with open loop/closed loop -- operation modes 20 - process design for 20, 21 - salt gradient formations in 22 IgG production 344-346 industrial relevant cell lines 368 integrated continuous bioprocessing 36-39 integrated perfusion-purification processes 142-144 intermolecular forces 6 intraparticle diffusion rate 10 intraparticle diffusion resistance 10, 22 ion exchange chromatography (IEC) 2 ion exchangers 4 ion exchange (IEX) technique 97 isoelectric point 16

k

- kSep6000 system 390
- kSep system configuration 390-392
- automated recipe screen for concentrate 392
- chamber capacity determination 391
- comparable processing time, cell recovery, and viability 392
- kSep technology 387-390
- automated concentration 395
- automated harvest clarification proces 397
- efficient washing by 397
- harvest clarification reliability, and recovery 398
- harvest process 395
- mechanism 388
- media replacement 395
- no change in LDH release after 393
- perfusion process 393, 394
- separation of cells, from microcarriers 398, 399
- viability and recovery of cells 396
- virus productivity comparison 396

I

Laboratory of Separation and Reaction Engineering (LSRE) 2 Langmuir binary isotherm, modified competitive 98 large-volume three-dimensional bags 404 Lean Six Sigma 51 ligand - binding 98 - of Streamline DEAE 8 lipopolysaccharide 300 liquid filtration, separation mechanisms in 410 Listeria monocytogenes 298 loading zone 260 - on BioSMB, protein A capture using multiple columns 271 - cation exchange loading zone optimization 284, 285 - of CMCC 262, 263 - comparison, from batch chromatography 261 - effect optimizing 275 - permutations configuration 271 - protein A loading zone optimization 271 low-shear process 392, 393

m

mAbs. *see* monoclonal antibodies (mAbs) material attributes 359 mathematical model 99 – applications 109–112 – dimensional considerations 100 – experimentation 103–105

- Langmuir-type adsorption mechanism, for protein and aggregates 101
- adsorption/desorption kinetic constant parameters 105–107
- batch contact vs. equilibrium experiment data 107
- -- breakthrough profile for β -lactoglobulin 106
- conventional Langmuir-type kinetic experiment 102
- -- material balance of region 102
- -- rate of adsorption of monomer 101, 102
- reaction rate as a function of concentration adsorbed 105
- Reynolds number for flow in a packed bed 103
- model vs. experimental results 108, 109
- protein denaturation 107, 108
- rate-limiting step in HIC process 99

MCSGP. see multicolumn countercurrent solvent gradient purification chromatography system (MCSGP) mechanically agitated suspension reactors 213, 214 membrane chromatography device 412 microcarriers 398 - separation of cells from 398 microfiltration 76, 135, 327, 340, 411 mixing hardware 406 monoclonal antibodies (mAbs) 36, 71 - bulk purification 270-280 - capture case studies 82, 232 – continuous protein A chromatography capture 82, 83 -- effect of clarification method on protein A performance 83, 84 - compounded annual growth rate 53 - continuous downstream processing for unit operation development 263-265 -- block flow diagram 264 -- surge vessels and balancing flows 265 - continuous multicolumn chromatography -- BioSMB protein A capture and viral inactivation 270, 271 - cost of goods (CoGs) analysis 89, 90-92 - CQA identification and function of 365 - downstream purification process (DSP) 72 -- evolutionary process 73 -- QbD method, applications 73 – – steps 72 -- template process, main areas 72-74 - fine purification 280-287 - formulation: continuous ultrafiltration 287 - 291- harvest and clarification 74 -- centrifugation 76 -- challenge and technology selection 74, 75 -- filtration 76, 77 -- impurity precipitation 76, 77 - heterogeneity 379 - pilot-scale demonstration of the integrated continuous process 291-293 - polishing 84-86 -- complete flow-through polishing case study 87, 88 -- technology selection strategy 86, 87 -- traditional DSP vs. flow-through based approach 85 - primary capture from clarified cell culture 78 -- chromatographic methods 79 -- continuous chromatography 79-82 -- protein A chromatography 78

- 502 Index
 - -- slurried bed methods 79
 - -- techniques 78
 - primary recovery 266-270
 - production platform process flow diagram 72
 - protein A affinity capture 236
 - protein A elution zone considerations 275–277
 - protein A loading zone optimization 271–275
 - surge vessels and balancing flows 265
 - therapies 71
 - typical batch production process of 481

multicolumn countercurrent solvent gradient purification chromatography system

- (MCSGP) 58, 59, 227, 229, 329 - applications 236, 237
- -- polishing 237-239
- case study 243-247
- complete cycle of 240
- in continuous manufacturing 251, 252
- designing 242, 243, 245
- discovery and development applications 247, 248
- impact on
- biologic supply chains 62
- chromatography market 64
- patent approval structure of biologic drugs 62, 63
- improving downstream processing of bispecific Mabs 61, 63
- limitations of system 64
- principle 239-241
- process 39, 40, 227-230, 232, 236, 237
- analytical tools for 252, 253
- -- principle 234-236
- as replacement for batch chromatography unit operations 249–251
- scale-up of 249
- start-up and steady state, for lysozyme purification 241
- in value chain 61
- vs. batch chromatography, in bispecific Mabs purification 61
- multimodal ligand 6
- multivariate data analysis (MVDA) system 292
- mutation rate 303
- myoglobin 16
- breakthrough curves at various NaCl concentrations 18
- competitive adsorption 18
- diffusion coefficients 19

- on Q-Sepharose FF anion exchanger resin 16, 17
 salt gradient ion exchange SMB
- salt gradient fon exchange sivil
- -- constraints to net fluxes separation in 23

n

net present cost (NPC) 257 nonlinear equilibrium isotherm 16 nonwoven fiber matrix-based bioreactor. *see* CellTank nucleic acids 1, 16, 71, 87, 135, 379

0

optimal downstream process – decision tree for selection 229 – operations 481, 482 overthe-counter (OTC) products 35

р

packed bed (PB) bioreactors 215-217 - commercialized reactors 216 particle imaging velocimetry (PIV) 141 particle size 6, 8, 14, 15, 77, 411 PAT. see process analytical technologies (PAT) pellicular adsorbent/inert core adsorbent 9 perfusion culture 203, 204 - manufacturing strategies 434-436 - processes 221 perfusion processes 116, 117, 342 - ATF/TFF in wave-induced bioreactor 342-353 - bioreactor and tanks in 117 - cell banking 117-119 - cost comparison 156, 157 - culture conditions 120-125 - inoculum development 117-119 - SDS-PAGE analysis 144 periodic countercurrent chromatography 143 pharmaceutical use isolator technology 413 pilot-scale demonstration of the integrated continuous process 291-293 polyamide 411 polydiallyldimethylammonium chloride (pDADMAC) 77 polyester (PE) 404 polymeric materials 408 precipitating agents 77 precipitation 75, 77, 83, 98, 143, 326, 327, 379 preferential interaction theory 98 preservatives 411 pressure/temperature conditions 409 process analytical technologies (PAT) 36, 184, 185, 235, 292, 293, 376

process complexity 115 product and component, transfer 413-415 - clamshell around a blast freeze bag 415 product batch, in continuous manufacturing 252 productivity gain 257 product-related impurities 71 Protein A 236 proteins - capture, by expanded bed technology 3 - glycosylation 378 - monomer/aggregate purification, modeling of 97 - production host, and COA 368, 369 - purification processes 257 - retention, on ionic surface of adsorbent 4 - separation and purification 1

– by salt gradient ion exchange SMB 15, 16
 Pseudomonas aeruginosa 299
 purification technologies 406–413

q

QSepharose FF 16 quality-by-design (QbD) 36, 360 – approach, steps 360 – components 360 – initiatives 433 – key steps for implementation 361

r

real-time release (RTR) 206 recombinant biopharmaceuticals 115 recombinant DNA technology 358, 458 recombinant mAbs 71 recombinant proteins 36 recombinant strains 299 recombinant therapeutic proteins 116, 368 regulatory aspects 47-50 - cGMP guidance 48 - FMEA principles 50 - improved process development 48 - Quality by Design and Process Analytical Technologies 48 - US FDA guidelines 47 repetitive elution peaks - for a four-column chromatography process 49 RepliGen's ATFTM System 214 reversed-phase chromatography (RPC) 16 reversed-phase high-performance liquid chromatography (RPHPLC) methodology 410 roller bottle systems 213

s

salt gradient formation 20, 21 salt gradient IE-SMB chromatography 16, 21 - proteins separation and purification in 15, 16.24 -- with open loop configuration 24-26 - separation region 21-24 sanitization agents 413 scalable perfusion technologies 167 seeding process 161, 162 - cell culture results -- using CELL-tainer[®] expansion set 161, 162 - growth rates in 162 - for mammalian cell culture 161 semicontinuous chromatography 436, 437 sequence variants identification by CQA 371 - 373settlers - gravitational settlers 126, 128 - inclined lamella settler 128 - laboratory-scale lamella settler system 129 - vertical settler 128 sieve retention 410 simulated moving bed (SMB) chromatography 2, 198, 235, 260, 329 - eight-column four-zone 231 simulation tool structure 439 single-pass tangential-flow filtration (SPTFF) 259 single-use and hybrid perfusion-type culture enabling products 195 single-use bags system 402, 403, 414 - advantage 403 - benefit of noncontact stirring 405 - good manufacturing practice 405 - large volume to small volume transfer 403 - mixing or agitation process activities 405 - preassembled and sterilized by 404 - process validation 405 - process validation studies 404 - qualification tests 404 single-use bioprocessing components 197 - commercially available upstream 197 single-use bioreactor (SUB) 155, 158, 194, 197 - advantages 155 - companies 197, 198 - cost reduction 155-157 - limitation 155 single-use centrifugation 387 single-use components existent, immature, and trends 402 single-use concepts

- in tangential-flow filtration (TFF)/cross-flow applications 413 single-use equipment 155 single-use final filling systems 417, 418 single-use liquid hold 402 single-use mixing systems 406 - benefits 406 single-use perfusion process 157 - disposable bioreactor oxygen transfer coefficient ($k_L a$) 157–159 as function of cell density at different specific oxygen uptake rates 158 - equipment requirements for 157-159 properties perfusion devices 160 - simplified seeding process 161, 162 - testing results 159, 161 single-use revolution, to enable process intensification and continuous processing 256-260 single-use systems 196, 197, 198 - coordinated implementation, with appropriate control 211 - example 202 - requirements, sponsors identified 199 single-use (SU) technology 196 - benefits with disposable components 256 - connections/disconnections 415, 416 - developments 196 - gap analysis 200 - key elements 415 - reliability of 402 - threats caused the design 411 - vs. stainless steel facility economics for production of monoclonal antibody 256 - welding thermoplastic tubing 416 single-use TFF cassettes and devices 413 size exclusion (gel filtration) chromatography (SEC) 15, 87, 231 size exclusion-simulated moving bed (SE-SMB) chromatography 16 SMB technology 16 staphylococcal enterotoxin B (SEB) 100 static binding capacity (SBC) 232 static capacity 98 stationary phase 2, 99 steam sterilization 408 sterilizing-grade filters 408, 409, 411 sterilizing-in-place (SIP) operation 117 stirred tank bioreactor (STR) 213 SUB. see single-use bioreactor (SUB) surfactants 410

t

tangential-flow filtration (TFF) processing 77, 198, 339, 386 tangential-flow microfiltration (µTFF) 76 teichoic acids 300 thermal stability 410 three-column capture process (3C-PCC) 235 three-column equipment 236 tool description 438 - key inputs/outputs of decisional tool 438, 439 trifunctional antibodies 59 twin-column CaptureSMB process 234, 235 twin-column MCSGP process - complete cycle 240 - phases 240 - principle 239 twin-column sequential loading process 237 two-column equipment 236

two packed bed bioreactors 217

и

ultrafiltration (UF) 340 ultrafiltration membrane 257 – structure 414 ultrasonic separators 221 upstream process (USP) 424 – characterization spaces 255 – impact on product quality attributes 374 – bioreactor optimization and scale up 374–379 – cell culture process operating parameters affecting 375

-- upstream process, tools used by 377

UV-based monitoring 252

UV signals 252

V

viruses 71

W

W-ATF bioreactor 340 WAVE BioreactorTM 340 wave D3TM separation technology 221 wave-induced bioreactors 339, 342 – perfusion run 342, 343 wave-induced disposable bioreactor 340 W-TFF bioreactor 340

Х

Xcellerex XDR Single-Use Bioreactor 214